Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 4/20 | 0.45 |
| ▸ | TERT | O14746 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692318 | 1.00 | EPHX2 (0.47) | EPHX2FAAHTERTPTPN1PPARG | |
| SCHEMBL465985 | 0.84 | PRKCA (0.54) | FAAHTERTCYP1A2MAPTCYP2C19 | |
| SCHEMBL992184 | 0.84 | PRKCA (0.54) | FAAHTERTCYP1A2MAPTCYP2C19 | |
| SCHEMBL31374704 | 0.81 | ALDH1A1 (0.58) | FAAHPPARGPPARDPPARAMAPT | |
| SCHEMBL28450589 | 0.80 | EPHX2 (0.50) | EPHX2FAAHTERTPTPN1PPARG | |
| SCHEMBL25140 | 0.79 | ALDH1A1 (0.43) | FAAHPPARGPPARDPPARAMAPT | |
| SCHEMBL158797 | 0.77 | ALDH1A1 (0.51) | EPHX2PPARGPPARDPPARAHSD17B10 | |
| SCHEMBL10016290 | 0.77 | TSHR (0.42) | EPHX2PTPN1PPARGPPARACYP1A2 | |
| SCHEMBL15205542 | 0.77 | TSHR (0.42) | EPHX2PTPN1PPARGPPARACYP1A2 | |
| SCHEMBL6686505 | 0.77 | TERT (0.66) | EPHX2FAAHTERTPTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-05-09 | — | — | US | disclosed |
| WO-2024073678-A2 | PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE | OMEGA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-03-28 | — | — | US | disclosed |
| EP-4328314-A2 | LIPID NANOPARTICLE METHODS AND COMPOSITIONS FOR PRODUCING ENGINEERED ERYTHROID CELLS | Tessera Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11904052-B2 | Methods for ameliorating infusion reactions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-20 | — | — | US | disclosed |
| US-20240050463-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-15 | — | — | US | disclosed |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-01 | — | — | US | disclosed |
| WO-2023225621-A2 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | OMEGA THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2011141703-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141704-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141705-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| US-20110201667-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-08-18 | — | — | US | disclosed |
| US-20110195127-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| WO-2011000106-A1 | IMPROVED CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000107-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000108-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | EPHX2 3171/4885FAAH 1988/4885TERT 2358/4885 |
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | EPHX2 3146/4885FAAH 2156/4885TERT 2551/4885 |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | EPHX2 3774/4885FAAH 2035/4885TERT 2828/4885 |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | LDLR, SNRPE, SARNP | EPHX2 3235/4885FAAH 3989/4885TERT 1679/4885 |
| US-20240050463-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | HAVCR2, FABP1, HDGF | EPHX2 561/4885FAAH 2822/4885TERT 2849/4885 |
| US-11904052-B2 | Methods for ameliorating infusion reactions | IL2, CD47, IL5 | EPHX2 1595/4885FAAH 1650/4885TERT 3039/4885 |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | EPHX2 3146/4885FAAH 2156/4885TERT 2551/4885 |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | EPHX2 3774/4885FAAH 2035/4885TERT 2828/4885 |
| US-20110201667-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | BST2, AGO2, SCARB1 | EPHX2 2783/4885FAAH 2338/4885TERT 3295/4885 |
| US-20110195127-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | APOB, LDLR, APOL1 | EPHX2 2492/4885FAAH 2334/4885TERT 3330/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | EPHX2 3019/4885FAAH 1966/4885TERT 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.